Galantamine
( DrugBank: Galantamine / KEGG DRUG: Galantamine hydrobromide, Galantamine )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 4 |
| 11 | Myasthenia gravis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 127 | Frontotemporal lobar degeneration | 1 |
6. Parkinson disease
Clinical trials : 2,817 / Drugs : 2,606 - (DrugBank : 348) / Drug target genes : 185 - Drug target pathways : 205
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
11. Myasthenia gravis
Clinical trials : 525 / Drugs : 355 - (DrugBank : 80) / Drug target genes : 75 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
127. Frontotemporal lobar degeneration
Clinical trials : 137 / Drugs : 175 - (DrugBank : 35) / Drug target genes : 44 - Drug target pathways : 112
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|